Literature DB >> 9165528

Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody.

S P Duddu1, P R Dal Monte.   

Abstract

PURPOSE: The purpose of this study is to highlight the importance of knowing the glass transition temperature, Tg, of a lyophilized amorphous solid composed primarily of a sugar and a protein in the interpretation of accelerated stability data.
METHODS: Glass transition temperatures were measured using DSC and dielectric relaxation spectroscopy. Aggregation of protein in the solid state was monitored using size-exclusion chromatography.
RESULTS: Sucrose formulation (Tg approximately 59 degrees C) when stored at 60 degrees C was found to undergo significant aggregation, while the trehalose formulation (Tg approximately 80 degrees C) was stable at 60 degrees C. The instability observed with sucrose formulation at 60 degrees C can be attributed to its Tg (approximately 59 degrees C) being close to the testing temperature. Increase in the protein/sugar ratio was found to increase the Tgs of the formulations containing sucrose or trehalose, but to different degrees.
CONCLUSIONS: Since the formulations exist in glassy state during their shelf-life, accelerated stability data generated in the glassy state (40 degrees C) is perhaps a better predictor of the relative stability of formulations than the data generated at a higher temperature (60 degrees C) where one formulation is in the glassy state while the other is near or above its Tg.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165528     DOI: 10.1023/a:1012144810067

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Formation of glasses from liquids and biopolymers.

Authors:  C A Angell
Journal:  Science       Date:  1995-03-31       Impact factor: 47.728

2.  The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.

Authors:  M L Roy; M J Pikal; E C Rickard; A M Maloney
Journal:  Dev Biol Stand       Date:  1992

3.  Importance of glass transition temperature in accelerated stability testing of amorphous solids: case study using a lyophilized aspirin formulation.

Authors:  S P Duddu; K Weller
Journal:  J Pharm Sci       Date:  1996-03       Impact factor: 3.534

4.  Thermally induced denaturation of lyophilized bovine somatotropin and lysozyme as impacted by moisture and excipients.

Authors:  L N Bell; M J Hageman; L M Muraoka
Journal:  J Pharm Sci       Date:  1995-06       Impact factor: 3.534

5.  The effect of excipients on glass transition temperatures for FK906 in the frozen and lyophilized states.

Authors:  J W Jang; S Kitamura; J K Guillory
Journal:  PDA J Pharm Sci Technol       Date:  1995 Jul-Aug

6.  The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids.

Authors:  B C Hancock; G Zografi
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

7.  The relationship between the glass transition temperature and water vapor absorption by poly(vinylpyrrolidone)

Authors:  C A Oksanen; G Zografi
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

8.  Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures.

Authors:  B C Hancock; S L Shamblin; G Zografi
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

9.  Dielectric analysis in the characterization of amorphous pharmaceutical solids. 1. Molecular mobility in poly(vinylpyrrolidone)-water systems in the glassy state.

Authors:  S P Duddu; T D Sokoloski
Journal:  J Pharm Sci       Date:  1995-06       Impact factor: 3.534

  9 in total
  30 in total

1.  Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.

Authors:  E D Breen; J G Curley; D E Overcashier; C C Hsu; S J Shire
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Characterization of murine monoclonal antibody to tumor necrosis factor (TNF-MAb) formulation for freeze-drying cycle development.

Authors:  X Ma; D Q Wang; R Bouffard; A MacKenzie
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

3.  Effect of vacuum drying on protein-mannitol interactions: the physical state of mannitol and protein structure in the dried state.

Authors:  Vikas K Sharma; Devendra S Kalonia
Journal:  AAPS PharmSciTech       Date:  2004-02-17       Impact factor: 3.246

4.  Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses.

Authors:  Sheri L Shamblin; Bruno C Hancock; Michael J Pikal
Journal:  Pharm Res       Date:  2006-08-29       Impact factor: 4.200

Review 5.  Silk-based stabilization of biomacromolecules.

Authors:  Adrian B Li; Jonathan A Kluge; Nicholas A Guziewicz; Fiorenzo G Omenetto; David L Kaplan
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

Review 6.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

7.  Influence of emulsion composition and spray-drying conditions on microencapsulation of tilapia oil.

Authors:  Hui Huang; Shuxian Hao; Laihao Li; Xianqing Yang; Jianwei Cen; Wanling Lin; Ya Wei
Journal:  J Food Sci Technol       Date:  2012-05-13       Impact factor: 2.701

Review 8.  The Principles of Freeze-Drying and Application of Analytical Technologies.

Authors:  Kevin R Ward; Paul Matejtschuk
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Non-Arrhenius protein aggregation.

Authors:  Wei Wang; Christopher J Roberts
Journal:  AAPS J       Date:  2013-04-25       Impact factor: 4.009

10.  Investigations into the stabilization of drugs by sugar glasses: III. The influence of various high-pH buffers.

Authors:  Jonas H C Eriksson; Wouter L J Hinrichs; Gerhardus J de Jong; Govert W Somsen; Henderik W Frijlink
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.